Literature DB >> 7797927

Quasispecies of hepatitis C virus and genetic drift of the hypervariable region in chronic type C hepatitis.

J H Kao1, P J Chen, M Y Lai, T H Wang, D S Chen.   

Abstract

The sequential variations of amino acid sequences in the hypervariable region (HVR)-1 of hepatitis C virus (HCV) and changes of viremia in 2 patients with different clinicopathologic courses of chronic hepatitis C were studied. By using polymerase chain reaction amplification, cloning, and sequencing of HVR-1, genetic heterogeneity of HCV was shown. The highest annual rate of consensus amino acid variation per 100 sites in HVR-1 of a patient with acute exacerbation was 15.4 versus 2.3 in a patient without acute exacerbation. The serial serum HCV titers were also quantified. An abrupt elevation of serum titer was associated with acute exacerbation, whereas constant viremia was observed when acute exacerbation did not occur. These results show that a quasispecies of HCV exists and patients with different courses of chronic hepatitis may have different sequential changes in virus titer and genetic drift of HVR-1.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7797927     DOI： 10.1093/infdis/172.1.261

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  15 in total

1.  Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort.

Authors:  J McAllister; C Casino; F Davidson; J Power; E Lawlor; P L Yap; P Simmonds; D B Smith
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

Review 2.  [Therapy of hepatitis C].

Authors:  D M Alscher; J C Bode
Journal:  Med Klin (Munich)       Date:  1997-03-15

Review 3.  The quasispecies of hepatitis C virus and the host immune response.

Authors:  P Farci; J Bukh; R H Purcell
Journal:  Springer Semin Immunopathol       Date:  1997

4.  Duration of HCV infection as a predictor of nonresponse to interferon.

Authors:  A Craxì; V Di Marco; C Cammà; P Almasio; S Magrin
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

5.  Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults.

Authors:  Sharon E Frey; Michael Houghton; Stephen Coates; Sergio Abrignani; David Chien; Domenico Rosa; Piero Pileri; Ranjit Ray; Adrian M Di Bisceglie; Paola Rinella; Heather Hill; Mark C Wolff; Viola Schultze; Jang H Han; Bruce Scharschmidt; Robert B Belshe
Journal:  Vaccine       Date:  2010-07-07       Impact factor: 3.641

6.  Multigene tracking of quasispecies in viral persistence and clearance of hepatitis C virus.

Authors:  Song Chen; Yu-Ming Wang
Journal:  World J Gastroenterol       Date:  2005-05-21       Impact factor: 5.742

7.  Assessment of hepatitis C virus sequence complexity by electrophoretic mobilities of both single-and double-stranded DNAs.

Authors:  Y M Wang; S C Ray; O Laeyendecker; J R Ticehurst; D L Thomas
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

Review 8.  Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine?

Authors:  Valerie J Kinchen; Andrea L Cox; Justin R Bailey
Journal:  Trends Microbiol       Date:  2018-04-24       Impact factor: 17.079

9.  Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy.

Authors:  J M Pawlotsky; G Germanidis; P O Frainais; M Bouvier; A Soulier; M Pellerin; D Dhumeaux
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

10.  Evolution of hypervariable region 1 of hepatitis C virus in primary infection.

Authors:  A Manzin; L Solforosi; E Petrelli; G Macarri; G Tosone; M Piazza; M Clementi
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.